Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $41.44.

ARWR has been the topic of a number of research reports. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Chardan Capital restated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Piper Sandler reduced their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 11,520 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $19.05, for a total value of $219,456.00. Following the completion of the sale, the chief executive officer now owns 3,764,252 shares in the company, valued at $71,709,000.60. This represents a 0.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Patrick O’brien sold 29,184 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $578,426.88. Following the transaction, the chief operating officer now directly owns 535,201 shares in the company, valued at approximately $10,607,683.82. This represents a 5.17 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 289,167 shares of company stock valued at $5,106,735. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Intech Investment Management LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at $659,000. Charles Schwab Investment Management Inc. raised its position in shares of Arrowhead Pharmaceuticals by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,006,935 shares of the biotechnology company’s stock valued at $19,504,000 after buying an additional 12,574 shares in the last quarter. Fisher Asset Management LLC lifted its stake in Arrowhead Pharmaceuticals by 941.0% during the third quarter. Fisher Asset Management LLC now owns 122,260 shares of the biotechnology company’s stock worth $2,368,000 after purchasing an additional 110,516 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Arrowhead Pharmaceuticals in the third quarter worth approximately $149,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of Arrowhead Pharmaceuticals by 40.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 55,188 shares of the biotechnology company’s stock valued at $1,069,000 after purchasing an additional 15,784 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $13.93 on Thursday. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The company has a market capitalization of $1.91 billion, a P/E ratio of -2.69 and a beta of 0.92. Arrowhead Pharmaceuticals has a 52 week low of $13.74 and a 52 week high of $30.41. The company’s 50 day moving average price is $18.35 and its two-hundred day moving average price is $19.72.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). On average, analysts expect that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.